RxDoctor Payments Data

Michael Goldstein, MD

Gastroenterology · Voorhees, NJNPI 1669469581

Payments from drug & device makers

$16,818in general payments, 2019–2025

Across 673 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$882
  • Takeda Pharmaceuticals U.S.A., Inc.$749
  • QOL Medical, LLC$497
  • Pfizer$334
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$8,98099%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,818 in reported general payments places this provider in the 90th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$275,284
Medicare patients
462
Services billed
13,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab23$155,241
LinzessLinaclotide56$52,167
ViberziEluxadoline11$20,195
CreonLipase/Protease/Amylase25$19,295
Mesalamine40$14,327
Ursodiol42$13,293
Famotidine572$10,588
Budesonide EcBudesonide20$10,204
Alosetron Hcl15$8,823
Dexlansoprazole DrDexlansoprazole11$8,722
Sucralfate98$7,471
Pantoprazole Sodium331$5,587
Lubiprostone22$3,338
Mesalamine ErMesalamine18$3,116
Colestipol Hcl17$3,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Viberzi, Creon$9,443$91,65892 claims
SandozLansoprazole$16$37313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →